Skip to content
Screener

PP&E (Net) at other companies

Arvinas logo
ArvinasARVN
$5.5M-17.9%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$39.97M-17.7%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$29.93M+3.0%
Septerna, Inc. logo
Septerna, Inc.SEPN
$4.33M-14.2%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$3.4M-6.0%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$5.28M-7.0%

Other financials

Income statement

See full
Revenue$9.0M-79.5%
Operating income-$94.2M-95.0%
Net income-$89.5M-106%
EPS (diluted)-$0.81-55.8%

Balance sheet

See full
Cash & equivalents$68.7M-19.4%
Total debt$58.1M+12.0%
Total equity$402.6M-10.0%
Total assets$535.5M-9.5%

Cash flow

See full
Operating cash flow-$96.6M-52.9%
CapEx$1.9M-27.6%
Free cash flow-$98.5M-49.6%

Valuation

See full
Market cap$2.62B+227%
Enterprise value$2.61B+240%
P/S71.2×+62.1×

Profitability

See full
Operating margin-982.4%-1,538pp
Net margin-928.4%-1,403pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-80.3%+113pp
Debt / equity0.1×0.0×
Current ratio6.3×-0.5×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001549595-26-000040
Line itemMay 31,2026November 30,2025
Prepaid expenses and other current assets12,95213,878
Total current assets456,481606,819
Operating lease right-of-use assets50,10750,517
Property and equipment, net20,00722,490
Restricted cash968968
Other assets7,9777,341
Total assets$535,540$688,135
Liabilities and stockholdersʼ equity

Item 1. Financial Statements (Unaudited)

FAQ

What is Nurix Therapeutics, Inc.'s PP&E (net)?
Nurix Therapeutics, Inc. (NRIX) reported PP&E (net) of $20.01M in Q1 2026.
How has Nurix Therapeutics, Inc.'s PP&E (net) changed year-over-year?
Nurix Therapeutics, Inc.'s PP&E (net) increased by 6.6% year-over-year, from $18.77M to $20.01M.
What is the long-term trend for Nurix Therapeutics, Inc.'s PP&E (net)?
Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s PP&E (net) has grown at a 27.5% compound annual growth rate (CAGR), from $6.67M to $22.49M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Ask your AI about Nurix Therapeutics, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude